Published in J Pharm Sci on May 01, 1999
Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science (1990) 6.70
Isolation and structure of a human fibroblast interferon gene. Nature (1980) 4.16
The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med (1977) 3.61
Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4'-chlorophenyl)thiazol-2-yl] thiosemicarbazide. Eur J Pharm Sci (1999) 3.59
Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest (1993) 2.59
Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine. J Infect Dis (1973) 2.53
Ultrasound treatment for treating the carpal tunnel syndrome: randomised "sham" controlled trial. BMJ (1998) 2.24
Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis (1982) 2.16
The course of untreated recurrent genital herpes simplex infection in 27 women. N Engl J Med (1981) 1.89
Monooctanoin, a dissolution agent for retained cholesterol bile duct stones: physical properties and clinical application. Gastroenterology (1980) 1.84
Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol. J Infect Dis (1982) 1.72
(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity. J Med Chem (1998) 1.61
Genital Herpesvirus homonis infection in mice. II. Treatment with phosphonoacetic acid, adenine arabinoside, and adenine arabinoside 5'-monophosphate. J Infect Dis (1977) 1.60
Alteration of mortality and pathogenesis of three experimental Herpesvirus hominis infections of mice with adenine arabinoside 5'-monophosphate, adenine arabinoside, and phosphonoacetic acid. Antimicrob Agents Chemother (1978) 1.57
Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob Agents Chemother (1987) 1.55
Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob Agents Chemother (2000) 1.49
Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. J Natl Cancer Inst (1978) 1.49
Investigation of factors influencing release of solid drug dispersed in inert matrices. 3. Quantitative studies involving the polyethylene plastic matrix. J Pharm Sci (1966) 1.47
Comparison of antiviral and antitumor activity of activated macrophages. Cell Immunol (1977) 1.42
Genital herpesvirus hominis infection in mice. I. Development of an experimental model. Infect Immun (1975) 1.41
Suppressed response to interferon inducation in mice infected with encephalomyocarditis virus, Semliki forest virus, influenza A2 virus, Herpesvirus hominis type 2, or murine cytomegalovirus. J Infect Dis (1977) 1.32
Differences in neurovirulence among isolates of Herpes simplex virus types 1 and 2 in mice using four routes of infection. J Infect Dis (1981) 1.29
Acyclovir treatment of experimental genital herpes simplex virus infections. Am J Med (1982) 1.29
Carbenoxolone in the long-term management of gastric ulcer. Practitioner (1969) 1.27
Summary of the II International Symposium on Cytomegalovirus. Antiviral Res (1998) 1.21
Treatment of experimental herpesvirus infections with phosphonoformate and some comparisons with phosphonoacetate. Antimicrob Agents Chemother (1978) 1.21
Effective antiviral chemotherapy in cytomegalovirus infection of mice. J Infect Dis (1976) 1.21
Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology (1985) 1.20
Effective treatment of murine cytomegalovirus infections with methylenecyclopropane analogues of nucleosides. Antiviral Res (1999) 1.20
Immunomodulation of host resistance to experimental viral infections in mice: effects of Corynebacterium acnes, Corynebacterium parvum, and Bacille calmette-guérin. J Infect Dis (1977) 1.20
Herpesvirus hominis infection in newborn mice: treatment with interferon inducer polyinosinic-polycytidylic acid. Antimicrob Agents Chemother (1975) 1.17
(Z)- and (E)-2-(hydroxymethylcyclopropylidene)-methylpurines and pyrimidines as antiviral agents. Antivir Chem Chemother (1998) 1.17
In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections. Antivir Chem Chemother (2001) 1.15
Effect of cytosine arabinoside and 5-iodo-2'-deoxyuridine on a cytomegalovirus infection in newborn mice. Antimicrob Agents Chemother (1976) 1.15
Immunomodulator-induced resistance against herpes simplex virus. Proc Soc Exp Biol Med (1977) 1.14
Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir. Antimicrob Agents Chemother (1984) 1.12
Theoretical and experimental studies of transport of micelle-solubilized solutes. J Pharm Sci (1982) 1.11
Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus. J Infect Dis (1998) 1.10
In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections. Antimicrob Agents Chemother (2000) 1.09
Model transport studies utilizing lecithin spherules. I. Critical evaluations of several physical models in the determination of the permeability coefficient for glucose. Biochim Biophys Acta (1972) 1.07
Clinical and virologic course of herpes simplex genitalis. West J Med (1979) 1.07
Sensitivity of herpes simplex virus types 1 and 2 to three preparations of human interferon. J Infect Dis (1980) 1.07
Bovid herpesvirus type-1 (infectious bovine rhinotracheitis virus)-induced thymidine kinase. Virology (1982) 1.07
NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements (2009) 1.06
Typing of herpes simplex virus with type-specific human immunoglobulin M in an indirect immunofluorescence assay. J Clin Microbiol (1982) 1.05
Relationships among carbonated apatite solubility, crystallite size, and microstrain parameters. Calcif Tissue Int (1999) 1.05
Effect of treatment with exogenous interferon, polyriboinosinic-polyribocytidylic acid, or polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex on Herpesvirus hominis infections in mice. J Infect Dis (1978) 1.04
Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis (1998) 1.04
The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res (1993) 1.04
Quantification of pore induction in human epidermal membrane during iontophoresis: the importance of background electrolyte selection. J Pharm Sci (2001) 1.03
2-5A synthetase activity induced by interferon alpha, beta, and gamma in human cell lines differing in their sensitivity to the anticellular and antiviral activities of these interferons. Virology (1982) 1.02
Combined effects of laser irradiation and chemical inhibitors on the dissolution of dental enamel. Caries Res (1992) 1.02
Synergism between recombinant human interferon and nucleoside antiviral agents against herpes simplex virus: examination with an automated microtiter plate assay. J Infect Dis (1985) 1.01
Effect of acyclovir treatment on acute and chronic murine cytomegalovirus infection. Am J Med (1982) 1.01
Methylene-gem-difluorocyclopropane analogues of nucleosides: synthesis, cyclopropene-methylenecyclopropane rearrangement, and biological activity. J Med Chem (2001) 1.01
Synthesis and antiviral activity of phosphoralaninate derivatives of methylenecyclopropane analogues of nucleosides. Antiviral Res (1999) 1.00
Permeation of hairless mouse skin I: Experimental methods and comparison with human epidermal permeation by alkanols. J Pharm Sci (1980) 0.99
Quantitative description of the effect of molecular size upon electroosmotic flux enhancement during iontophoresis for a synthetic membrane and human epidermal membrane. J Pharm Sci (1996) 0.98
Functional impact of unvarying exercise program in women after menopause. Am J Phys Med Rehabil (1998) 0.98
Herpesvirus hominis infection in newborn mice: comparison of the therapeutic efficacy of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyladenine. Antimicrob Agents Chemother (1975) 0.98
(S)-1-(3-hydroxy-2-(phosphonylmethoxy)propyl)cytosine (HPMPC): a potent antiherpesvirus agent. Adv Exp Med Biol (1990) 0.98
Replication of human cytomegalovirus in severe combined immunodeficient mice implanted with human retinal tissue. J Infect Dis (2001) 0.97
The effect of temperature upon the permeation of polar and ionic solutes through human epidermal membrane. J Pharm Sci (1995) 0.96
Release of medroxyprogesterone acetate from a silicone polymer. J Pharm Sci (1970) 0.96
Effect of treatment with exogenous interferon, polyinosinic acid-polyctyidylic acid or polyinosinic acid-polycytidylic acid-poly-L-lysine complex on encephalomyocarditis virus infections in mice. Antimicrob Agents Chemother (1976) 0.96
A novel skeletal drug delivery system for anti-bacterial drugs using self-setting hydroxyapatite cement. Chem Pharm Bull (Tokyo) (1990) 0.96
Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs. J Infect Dis (1988) 0.96
Antiviral activities of biflavonoids. Planta Med (1999) 0.96
Self-setting hydroxyapatite cement: a novel skeletal drug-delivery system for antibiotics. J Pharm Sci (1992) 0.95
Theoretical model studies of drug absorption and transport in the gastrointestinal tract.i. J Pharm Sci (1970) 0.95
Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J Pharm Sci (1969) 0.95
Transdermal iontophoretic drug delivery: mechanistic analysis and application to polypeptide delivery. J Pharm Sci (1989) 0.95
Hindered diffusion of polar molecules through and effective pore radii estimates of intact and ethanol treated human epidermal membrane. Pharm Res (1994) 0.95
Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. Antiviral Res (1991) 0.94
Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J Pharm Sci (1970) 0.94
Iontophoretic transport across a synthetic membrane and human epidermal membrane: a study of the effects of permeant charge. J Pharm Sci (1997) 0.94
Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J Clin Invest (2000) 0.93
2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol Pharmacol (1987) 0.93
Acyclovir treatment of disseminated herpes simplex virus type 2 infection in weanling mice: alteration of mortality and pathogenesis. Antiviral Res (1986) 0.93
Murine cytomegalovirus induces a Sjögren's syndrome-like disease in C57Bl/6-lpr/lpr mice. Arthritis Rheum (1998) 0.93
Studies on the toxicity and antiviral activity of various polynucleotides. Antimicrob Agents Chemother (1973) 0.93
Synthesis and enantioselectivity of the antiviral effects of (R,Z)-,(S,Z)-methylenecyclopropane analogues of purine nucleosides and phosphoralaninate prodrugs: influence of heterocyclic base, type of virus and host cells. Antivir Chem Chemother (2000) 0.92
Pore induction in human epidermal membrane during low to moderate voltage iontophoresis: A study using AC iontophoresis. J Pharm Sci (1999) 0.92
Herpes simplex virus type 2 infection induced apoptosis in peritoneal macrophages independent of Fas and tumor necrosis factor-receptor signaling. Viral Immunol (1999) 0.92
Acyclovir treatment of experimental genital herpes simplex virus infections. I. Topical therapy of type 2 and type 1 infections of mice. Antiviral Res (1983) 0.92
Mechanistic study of the influence of micelle solubilization and hydrodynamic factors on the dissolution rate of solid drugs. J Pharm Sci (1968) 0.92
Synthesis and antiviral evaluation of 1-O-hexadecylpropanediol-3-P-acyclovir: efficacy against HSV-1 infection in mice. Nucleosides Nucleotides Nucleic Acids (2000) 0.92
Mechanism of drug release from an acrylic polymer-wax matrix tablet. J Pharm Sci (1994) 0.92
Cholesterol solubility in organic solvents. J Pharm Sci (1979) 0.91
Apoptosis mediated by Fas but not tumor necrosis factor receptor 1 prevents chronic disease in mice infected with murine cytomegalovirus. J Clin Invest (1998) 0.91
Antiviral activity of an extract of Brucella abortus: induction of interferon and immunopotentiation of host resistance. Proc Soc Exp Biol Med (1976) 0.91